IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival.

Publication date: Jun 01, 2021

Indoleamine 2-3 dioxygenase 1 (IDO1) expression may contribute to immunologic escape by melanoma metastases. However, a recent clinical trial failed to identify any clinical benefits of IDO1 inhibition in patients with unresectable metastatic melanoma, and prior characterizations of IDO1 expression have predominately studied primary lesions and local metastases, generating uncertainty regarding IDO1 expression in distant metastases. We hypothesized that IDO1 expression in such lesions would be low and correlated with decreased overall survival (OS). Metastases from patients (n=96) with stage IIIb to IV melanoma underwent tissue microarray construction and immunohistochemical staining for IDO1. Th1-related gene expression was determined quantitatively. Associations between OS and IDO1 expression were assessed with multivariate models. Of 96 metastatic lesions, 28% were IDOpos, and 85% exhibited IDO1 expression in

Concepts Keywords
Dioxygenase DNA Chip
Genes Medicine
Immunologic Metastasis
Indoleamine Clinical medicine
Melanoma Melanoma
Microarray Immune system
Staining Indoleamine 2,3-dioxygenase
Medical specialties
Unresectable metastatic melanoma
Stage IIIb melanoma
Survival OS Metastases


Type Source Name
disease MESH uncertainty
pathway KEGG Melanoma
disease MESH Melanoma

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *